Personalised medicine for nonsmall cell lung cancer

Céline Mascaux; Pascale Tomasini; Laurent Greillier; Fabrice Barlesi

doi:10.1183/16000617.0066-2017

Personalised medicine for nonsmall cell lung cancer

Eur Respir Rev. 2017 Nov 15;26(146):170066. doi: 10.1183/16000617.0066-2017. Print 2017 Dec 31.

Authors

Céline Mascaux^{1

2}, Pascale Tomasini^{3

2}, Laurent Greillier^{3

2}, Fabrice Barlesi^{3

2}

Affiliations

¹ Aix Marseille University, Assistance Publique Hôpitaux de Marseille, Multidisciplinary Oncology and Therapeutic Innovations Dept, Marseille, France celine.mascaux@ap-hm.fr.
² Aix Marseille University, Inserm U911 CRO2, Marseille, France.
³ Aix Marseille University, Assistance Publique Hôpitaux de Marseille, Multidisciplinary Oncology and Therapeutic Innovations Dept, Marseille, France.

Abstract

After years of standard care prescribed to cancer patients without any selection except the primary site and histology of the tumour, the era of precision medicine has revolutionised cancer care. Personalised medicine refers to the selection of patients for specific treatment based on the presence of specific biomarkers which indicate sensitivity to corresponding targeted therapies and/or lower toxicity risk, such that patients will have the greatest chance of deriving benefit from the treatments. Here, we review personalised medicine for nonsmall cell lung cancer.

Publication types

Review

MeSH terms

Antineoplastic Agents / adverse effects
Antineoplastic Agents / therapeutic use*
Biomarkers, Tumor / genetics
Biomarkers, Tumor / metabolism
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / genetics
Carcinoma, Non-Small-Cell Lung / metabolism
Carcinoma, Non-Small-Cell Lung / pathology
Gene Rearrangement
Humans
Lung Neoplasms / drug therapy*
Lung Neoplasms / genetics
Lung Neoplasms / metabolism
Lung Neoplasms / pathology
Molecular Diagnostic Techniques
Molecular Targeted Therapy
Mutation
Precision Medicine*
Risk Factors
Signal Transduction / drug effects

Substances

Antineoplastic Agents
Biomarkers, Tumor